Introducing Arthrosamid®

Redefining treatment for knee OA, without surgery

Arthrosamid® is a non-biodegradable 2.5 iPAAG injectable implant that delivers long-lasting pain relief — improving the quality of life for patients with knee OA.

What is Arthrosamid®?

Arthrosamid® is a single, minimally invasive, long-lasting knee OA treatment — a non-biodegradable injectable polyacrylamide hydrogel (2.5 iPAAG) for intra-articular use.

Relieve pain and improve the function of the knee affected by knee OA, with a simple, one-step outpatient procedure.

Pioneering

Arthrosamid® is a first-in-class synovial scaffolddelivered as a single, minimally invasive out-patient procedure performed under local anaesthesia, with ultrasound guidance.

Proven

Arthrosamid® is safe for intended use and has undergone more than 20 years of research and development.

Pain Relief Treatment

A single, minimally invasive, long-lasting knee OA treatment, Arthrosamid® has demonstrated an improvement in quality of life with patients in clinical trials reporting a reduction in pain by Week 4 — and lasting over 3 years.

What is 2.5 iPAAG?

Intra-articular injectable polyacrylamide hydrogel (2.5 iPAAG) in Arthrosamid® is made up of 2.5% cross-linked polyacrylamide and 97.5% water.

Biocompatible: permeable to salts and organic molecules the hydrogel is able to integrate with soft tissue
Viscoelastic: cross-linked chains of polymer allow flexible shea
Non-degradable: structural stability of hydrogel provides longevity of action

iPAAG: injectable polyacrylamide hydrogel

Undergone

over 20 years

of research and development

Around

1,200,000 syringes of 2.5 iPAAG

have been made for human use.

Arthrosamid® remains

safe and effective

for its intended use 3 years after treatment.

Biocompatible

permeable to salts and organic molecules the hydrogel is able to integrate with soft tissue

Viscoelastic

cross-linked chains of polymer allow flexible shear

Non-degradable

structural stability of hydrogel provides longevity of action

Arthrosamid® is the first and only approved 2.5 iPAAG treatment that permanently integrates into the synovial membrane — decreasing joint stiffness, diminishing pain, and improving the function of the knee.

Acting as a synovial scaffold , Arthrosamid® distributes within the synovial fluid to fully integrate into the synovial membrane , thickening it and providing a physical barrier that breaks the inflammatory cycle to relieve pain.

Mode of Action — let’s take a closer look

Obehandlad artros knä: ledvätskan förlorar sina viskoelastiska egenskaper. Ledhinnan innehåller en ansamling av inflammatoriska celler som är ett förstadium till smärta och svullnad.

Arthrosamid is injected into the joint cavity, distributes within the joint fluid, and begins to adhere to the synovial lining.

Macrophage-like synoviocytes (MLS) enter the hydrogel but are unable to phagocytise it.

The MLS cells differentiate into fibroblast-like synoviocytes (FLS) which start integrating through the hydrogel, creating a thin vessel-bearing fibrous network.

A new layer of intima forms on the top of the integrated iPAAG synovial membrane. This new layer consists of scattered non-inflammatory type cells, with the iPAAG acting as a scaffold within the sub-intima layer. This process takes 1 month.

The thickening of the synovial sub-intima layer causes distancing of the inflammatory cells and breaks the inflammatory cycle.

Obehandlad artros knä: ledvätskan förlorar sina viskoelastiska egenskaper. Ledhinnan innehåller en ansamling av inflammatoriska celler som är ett förstadium till smärta och svullnad.

How to inject Arthrosamid®

Click or scroll to continue

Oral antibiotics must be taken 1-2 hours before injection to reduce risk of infection. If available, use Ultrasound to ensure correct placement of needle into knee joint space.

-2:00

2. Conduct the procedure using aseptic conditions and a no-touch technique. Swab at least 5cm around the injection site and use a local anaesthetic to numb the skin around it. Prepare 6 x 1ml Arthrosamid® syringes by removing from blister packs and laying on table for easy access.